Cargando…

Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database

INTRODUCTION: For many, atopic dermatitis (AD) is not adequately controlled with topical regimens. This analysis examined treatment using advanced therapies and associated costs. METHODS: The IQVIA Health Plan Claims data set was analyzed. Patients aged ≥ 12 years with AD who newly initiated advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichenfield, Lawrence F., DiBonaventura, Marco, Xenakis, Jason, Lafeuille, Marie-Helene, Duh, Mei Sheng, Fakih, Iman, Levenberg, Mark, Cappelleri, Joseph C., Sikirica, Vanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367964/ https://www.ncbi.nlm.nih.gov/pubmed/32607738 http://dx.doi.org/10.1007/s13555-020-00413-8

Ejemplares similares

Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
por: Wu, Jashin J., et al.
Publicado: (2022)

What’s New in Topicals for Atopic Dermatitis?
por: Kleinman, Elana, et al.
Publicado: (2022)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the “con” view
por: Ginsberg, David N., et al.
Publicado: (2016)

Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
por: Silverberg, J.I., et al.
Publicado: (2021)

Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study
por: Landis, Megan N., et al.
Publicado: (2022)

Economic Burden of Atopic Manifestations in Patients With Atopic Dermatitis - Analysis of Administrative Claims
por: Suh, Dong-Churl, et al.
Publicado: (2007)

Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis
por: Kwatra, Shawn G., et al.
Publicado: (2021)

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases
por: Ortsäter, Gustaf, et al.
Publicado: (2022)

Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis
por: Hagenström, Kristina, et al.
Publicado: (2021)

All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States
por: Mostaghimi, Arash, et al.
Publicado: (2022)

Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases
por: Shrestha, Sulena, et al.
Publicado: (2017)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting
por: Eichenfield, Lawrence F., et al.
Publicado: (2022)

The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
por: Girolomoni, Giampiero, et al.
Publicado: (2020)

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
por: Meyers, Kristin J., et al.
Publicado: (2021)

Cost of Care of Atopic Dermatitis in India
por: Handa, Sanjeev, et al.
Publicado: (2015)

Quantifying Costs Associated with Atopic Dermatitis
por: Ellis, Charles N., et al.
Publicado: (2003)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

Health‐care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis
por: Igarashi, Atsuyuki, et al.
Publicado: (2019)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
por: Mostaghimi, Arash, et al.
Publicado: (2022)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
por: Bloudek, Lisa, et al.
Publicado: (2022)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Consensus Conference on Clinical Management of pediatric Atopic Dermatitis
por: Galli, Elena, et al.
Publicado: (2016)

Cost Effectiveness of Emollients in the Prevention of Relapses in Atopic Dermatitis
por: Cabout, Elise, et al.
Publicado: (2020)

Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review
por: Silverberg, J.I., et al.
Publicado: (2022)

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents
por: Ständer, S., et al.
Publicado: (2022)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review
por: Mostaghimi, Arash, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbclsld7n31j1uvkk568gjutg3